Khondrion, a spin-off from the Radboud university medical center, has appointed Herma Renkema as Chief Early Development Officer with effect from 1 July 2020. She will strongly focus on the development of new medicines for mitochondrial diseases.
Dr. Herma Renkema has been working as a researcher at Khondrion since 2016. In her new role, she will be responsible for the preclinical development strategy and day-to-day operations in Khondrion’s laboratories. As a medical biologist, Renkema has built up considerable expertise in the field of mitochondrial biochemistry. Before joining Khondrion, she worked at the University of Amsterdam, The Institute of Medical Technology in Tampere, Finland and the Radboudumc. She has more than forty publications on mitochondrial research to her name.
“Khondrion is currently in an exciting development phase,” said Renkema, “The focus is on making new treatments available to patients with mitochondrial disease. So far, we have been able to rapidly develop the pipeline of potential drugs. We will continue to focus on this with the entire team, with the aim of improving the quality of life of this group of patients as soon as possible. ”
Jan Smeitink, CEO of Khondrion: “Herma Renkema has a lot of biochemical knowledge that is of great value to our company. As a member of the management, with the responsibility to add new products to our pipeline, she will play an important role in the further development of the company. In addition, Khondrion is making good progress with the drug Sonlicromanol, which is currently in research phase IIb for the treatment of some mitochondrial disorders.